Kroger stock falls after Amazon announces major grocery expansion
LONDON - Solvonis Therapeutics plc (LSE:SVNS) Chairman Dennis Purcell will join a panel discussion at an investor event hosted by Lucid (NASDAQ:LCID) Capital Markets on Thursday, July 17, the clinical-stage biopharmaceutical company announced Monday.
The panel, which begins at 2:00 p.m. ET, will feature Purcell alongside Stelios Papadopoulos, Chair of Exelixis (NASDAQ:EXEL), and Jeremy Levin, Chair and CEO of Ovid Therapeutics (NASDAQ:OVID). Elemér Piros, Managing Director and Senior Biotech Analyst at Lucid Capital Markets, will moderate the discussion.
According to the company’s press release, the session will focus on leadership, innovation, and strategic capital deployment in the biotechnology sector.
Purcell, who founded Aisling Capital, has over 30 years of experience in life sciences investment and has deployed more than $15 billion across over 200 companies throughout his career.
Solvonis Therapeutics is currently developing medicines for addiction and mental health disorders and operates an AI-enabled central nervous system drug discovery platform.
The event will take place at 7:00 p.m. British Summer Time for UK-based participants.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.